Bull case
MBX Biosciences is attractive because its Precision Endocrine Peptide platform is designed to deliver longer-acting, smoother peptide exposure, which could solve major adherence and tolerability issues that limit current endocrine and metabolic therapies. The lead obesity asset MBX 4291 has shown early blinded Phase 1 data with up to 16% weight loss after eight weeks, a delayed Tmax of about 13–14 days, and low gastrointestinal burden, supporting the thesis that once-monthly dosing can differentiate it in a growing market where physicians cite GI tolerability and less frequent dosing as top unmet needs. Canvuparatide adds further upside, with Phase 3 oPTimize positioned to make it the first once-weekly PTH replacement for an estimated ~$8B hypoparathyroidism market, while the company’s pro forma cash of about $440M and runway into 2029 reduce near-term financing risk.